Recent machine-extracted executive movements from SEC 8-K Item 5.02 filings, source-linked. Every card cites the SEC source.
Showing 651–700 of 18397
David Moon, President and Chief Executive Officer of the Company, has notified the Board of Directors (the “Board”) of his intention to retire following the appointment of his replacement.
On May 4, 2026, Mike Mancini, Chief Financial Officer of the Company, submitted his resignation to the Company effective as of May 6, 2026.
On May 6, 2026, the Company announced that Aidan Ryan, 42, has been appointed as the Interim Chief Financial Officer.
In connection with the foregoing, on April 1, 2026, the Board appointed Don E. Ray to serve as Interim Chief Financial Officer of the Company.
Following the Committee’s review and recommendation, the Independent Board of Directors approved the termination of Mr. Perry’s employment for Cause, with notice of such termination delivered on May 2, 2026.
On May 1, 2026, Fiona Fitzmaurice ceased serving as Chief Financial Officer of Birchtech Corp.
Effective May 1, 2026, the Company appointed Michael Mioska as its Chief Financial Officer.
On May 1, 2026, TruGolf Holdings, Inc. (the “Company”) entered into an employment letter (the “Employment Letter”) with Steven Passey to serve as the Company’s Chief Financial Officer effective May 15, 2026.
On April 30, 2026, Bimergen Energy Corporation (“Bimergen”) Compensation Committee entered into amendments of its employment agreements with Robert J. Brilon as Co-Chief Executive Officer and Chief Financial Officer (the “Brilon Agreement”) and Cole W. Johnson as Co-Chief Executive Officer and President (the “Johnson Agreement”) effective April 1, 2026.
On April 30, 2026, Bimergen Energy Corporation (“Bimergen”) Compensation Committee entered into amendments of its employment agreements with Robert J. Brilon as Co-Chief Executive Officer and Chief Financial Officer (the “Brilon Agreement”) and Cole W. Johnson as Co-Chief Executive Officer and President (the “Johnson Agreement”) effective April 1, 2026.
On May 5, 2026, the Boards of Directors of Orrstown Financial Services, Inc. (the “Company”) and its wholly-owned subsidiary Orrstown Bank (the “Bank”) elected Adam L. Metz as the President, Chief Executive Officer and Director of the Company and the Bank, respectively, effective upon the retirement of Thomas R. Quinn, Jr. from those positions with the Company and the Bank at the close of business on June 1, 2026
effective upon the retirement of Thomas R. Quinn, Jr. from those positions with the Company and the Bank at the close of business on June 1, 2026
On May 4, 2026, the Board appointed Terrie Kellmeyer, PhD as the Company's Interim Chief Executive Officer.
On April 30, 2026, a special committee (the "Special Committee") composed of independent directors of the Board of Directors (the "Board") of Anavex Life Sciences Corp. (the "Company") terminated the employment of Christopher Missling, PhD as the Company's Chief Executive Officer for Cause (as defined in the Employment Agreement, dated as of June 27, 2013, between Dr. Missling and the Company, as amended and restated), effective immediately, for, among other things, conduct that the Special Committee believed was inconsistent with Company policy.
On May 5, 2026, Integra LifeSciences Holdings Corporation (the "Company") announced the appointment of Dr. Stuart M. Essig to serve as its President and Chief Executive Officer, effective as of May 1, 2026 (the "Start Date").
Dr. Essig succeeds Mojdeh Poul, who is departing from her role as the Company's President and Chief Executive Officer and as a member of the Company's Board of Directors (the "Board") effective as of the end of the day on April 30, 2026 (the "Separation Date").
the board of the Surviving Corporation appointed Mr. Wann as President and Chief Executive Officer and Tiffany Moseley as Senior Vice President and Chief Financial Officer
the board of the Surviving Corporation appointed Mr. Wann as President and Chief Executive Officer and Tiffany Moseley as Senior Vice President and Chief Financial Officer
On May 5, 2026, CF Industries Holdings, Inc. ("CF Industries" or the "Company") announced that Andrew T. Scribner has been elected executive vice president and chief financial officer (principal financial officer), effective May 26, 2026 (the "Effective Date").
On an interim basis, Kenneth C. “Casey” Keller, our President and Chief Executive Officer, has assumed Ms. Schum’s and Mr. Vogel’s responsibilities.
On April 29, 2026, J. Ross Franklin notified Atlantic American Corporation (the “Company”) of his decision to resign as Vice President, Chief Financial Officer and Secretary of the Company, effective May 27, 2026.
Effective upon Mr. Ware’s appointment as the CFO, Justin Vu resigned as Chief Financial Officer of the Company as well as all other positions with the Company, its subsidiaries and its affiliates.
Effective April 29, 2026, iAnthus Capital Holdings, Inc. (the “Company”) appointed Jason Ware, age 52, as the Company’s Chief Financial Officer (the “CFO”).
As a result, Yann Brandt departed as the Company’s President and Chief Executive Officer and as a Company director, effective as of April 29, 2026.
On April 29, 2026, the Board of Directors of the Company (the “Board”) appointed Anthony Carroll as the Company’s President and Chief Executive Officer, effective as of April 29, 2026.
As such, as of the Effective Date, Ms. Vaughn will no longer serve as the Company’s principal accounting officer.
On May 4, 2026, pursuant to a nomination by a stockholder of Apimeds Pharmaceuticals US, Inc., a Delaware corporation (the " Company "), the board of directors of the Company (the " Board ") appointed Sungjoon Chae to serve as Co-Chief Executive Officer of the Company, effective as of such date.
Effective the same date: (i) the Company appointed its Chairman of the Board, Moishe Gubin, as its Chief Executive Officer and principal executive officer; and (ii) the Bank appointed Mr. Gubin as its Chief Executive Officer.
On May 1, 2026, Timothy Terry retired as principal executive officer of OptimumBank Holdings, Inc. (the “Company”) and as President and Chief Executive Officer of its wholly-owned subsidiary, OptimumBank.
On February 27, 2026, the Company announced that Gregory P. Giometti, the Company’s Interim Chief Financial Officer, would depart the Company on May 8, 2026
on April 30, 2026, the Company’s Board of Directors appointed Susan D. Davies, who currently serves as the Company’s Chief Accounting Officer and Global Controller, to serve as Interim Chief Financial Officer, effective as of May 8, 2026
The Corporation’s Senior Vice President and Chief Financial Officer, Nelson Urdaneta, will act as the Corporation’s principal accounting officer effective upon Mr. Scribner’s departure on an interim basis and in addition to his current duties.
the Board, at the recommendation of the Nominating and Corporate Governance Committee, appointed Alton Shader to serve as Chief Executive Officer of the Company ("CEO") and a Class II director of the Board, effective as of May 26, 2026
On May 1, 2026, Amanda Whalen informed the Company of her intention to step down from her role as Chief Financial Officer of the Company.
On April 30, 2026, Michelle Hook informed the Chief Executive Officer and General Counsel and Secretary of Portillo’s Inc. (the “Company”) that she will depart from her role as Chief Financial Officer of the Company, effective May 5, 2026.
On April 28, 2026, the Corporation elected Susan Buchanan as Vice President and Chief Accounting Officer (principal accounting officer) of the Corporation effective July 1, 2026.
On April 30, 2026, as part of its management succession planning, the Board unanimously approved the appointment of Richard A. Jackson, 50, as Occidental’s President and CEO and as a member of the Board, in each case effective as of the Transition Date.
On April 30, 2026, Vicki Hollub, President and Chief Executive Officer (“CEO”) of Occidental Petroleum Corporation (“Occidental”), informed the Board of Directors of Occidental (the “Board”) of her decision to retire, effective as of June 1, 2026 (the “Transition Date”).
On May 4, 2026, Edwards Lifesciences Corporation, a Delaware corporation (the “Company”), announced that Theodora Mistras has been appointed as the Corporate Vice President, Chief Financial Officer of the Company, effective May 29, 2026, to succeed Scott B. Ullem in that position.
James Rinn provided notice to PSQ Holdings, Inc. (the “Company”) of his resignation from the position of Chief Financial Officer of the Company, effective April 30, 2026.
effective immediately after the Effective Time, the Company appointed Ying Luo, Ph.D. as Chief Executive Officer and President of the Company and to the Board as a Class I director.
Ruoyu Chen, who resigned from her position as Chief Financial Officer on such date.
the Company appointed Thomas Eastling as Chief Financial Officer of the Company, to succeed Ruoyu Chen, who resigned from her position as Chief Financial Officer on such date.
On May 4, 2026, the Board of Directors of the Company (the “Board”) appointed Paul Campbell, Viatris’ current Chief Accounting Officer and Corporate Controller, to also serve as interim Chief Financial Officer of the Company, effective May 8, 2026, until a permanent Chief Financial Officer is appointed by the Board.
On May 1, 2026, Theodora (“Doretta”) Mistras informed Viatris Inc. (the “Company”) that she would voluntarily cease to serve as Chief Financial Officer to pursue another professional opportunity.
Dr. Elisabet de los Pinos, the Company’s founder, who has notified the Company of her departure from her role at the Company as Chief Executive Officer and President and as a director of the Company, effective as of the Effective Date
the Board of Directors (the “Board”) of Aura Biosciences, Inc. (the “Company”) appointed Natalie Holles as the Company’s Chief Executive Officer and President and as a Class I director with a term expiring at the Company’s 2028 annual meeting of stockholders, effective as of April 30, 2026
the Board appointed Brian Burkavage, the Company’s current Senior Vice President, Finance, to serve as the Company’s principal financial officer and principal accounting officer, effective as of the Effective Time.
the Board of Directors (the “Board”) of Damora Therapeutics, Inc. (the “Company”) determined that, effective as of May 1, 2026 (the “Effective Time”), Lori Firmani would cease serving as the Company’s Chief Financial Officer.
On May 4, 2026, Adeia Inc. (the “Company” or “Adeia”) announced that Paul E. Davis, the Company’s chief executive officer, notified the Company and the Board of Directors (the “Board”) on May 4, 2026, of his intention to step down as the Company’s chief executive officer and as a member of the Board to focus on his health and personal pursuits.
Recent executive movements from 8-K Item 5.02 filings, source-linked. Cards are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.